Editorial: Women in science—Precision medicine 2021

por Chen, Alice P., Tan, Antoinette
Publicado 2023

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

por Jagosky, Megan, Tan, Antoinette R
Publicado 2021

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer

por Heeke, Arielle L., Tan, Antoinette R.
Publicado 2021

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer

por Matusz-Fisher, Ashley, Tan, Antoinette R.
Publicado 2022

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

por Tan, Antoinette R., O’Shaughnessy, Joyce, Cao, Subing, Ahn, Sarah, Yi, John S.
Publicado 2023

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function

por Tan, Antoinette R., Sarantopoulos, John, Lee, Lucy, Reyderman, Larisa, He, Yi, Olivo, Martin, Goel, Sanjay
Publicado 2015

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer

por Sammons, Sarah, Elliott, Andrew, Barroso-Sousa, Romualdo, Chumsri, Saranya, Tan, Antoinette R., Sledge, George W., Tolaney, Sara M., Torres, Evanthia T. Roussos
Publicado 2023

Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

por Chow, Laura Q. M., Smith, David C., Tan, Antoinette R., Denlinger, Crystal S., Wang, Ding, Shepard, Dale R., Chaudhary, Archana, Lin, Yong, Gao, Ling
Publicado 2016

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma...

por Morris, John C., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Reiss, Michael, Hsu, Frank J., Berzofsky, Jay A., Lawrence, Donald P.
Publicado 2014

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

por Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Publicado 2018

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

por Pegram, Mark D., Hamilton, Erika P., Tan, Antoinette R., Storniolo, Anna Maria, Balic, Kemal, Rosenbaum, Anton I., Liang, Meina, He, Peng, Marshall, Shannon, Scheuber, Anita, Das, Mayukh, Patel, Manish R.
Publicado 2021

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

por Khoury, Katia, Tan, Antoinette R., Elliott, Andrew, Xiu, Joanne, Gatalica, Zoran, Heeke, Arielle L., Isaacs, Claudine, Pohlmann, Paula R., Schwartzberg, Lee S., Simon, Michael, Korn, W. Michael, Swain, Sandra M., Lynce, Filipa
Publicado 2020

The current state of molecular testing in the treatment of patients with solid tumors, 2019

por El‐Deiry, Wafik S., Goldberg, Richard M., Lenz, Heinz‐Josef, Shields, Anthony F., Gibney, Geoffrey T., Tan, Antoinette R., Brown, Jubilee, Eisenberg, Burton, Heath, Elisabeth I., Phuphanich, Surasak, Kim, Edward, Brenner, Andrew J., Marshall, John L.
Publicado 2019

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients

por Shahid, Zainab, Patrick, Alicia L., Wallander, Michelle L., Donahue, Erin E., Trufan, Sally J., Tan, Antoinette R., Hwang, Jimmy J., Burgess, Earle F., Ragon, Brittany, Ghosh, Nilanjan, Grunwald, Michael R., Voorhees, Peter M., Copelan, Edward A., Raghavan, Derek
Publicado 2023

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

por Tan, Antoinette R., Wright, Gail S., Thummala, Anu R., Danso, Michael A., Popovic, Lazar, Pluard, Timothy J., Han, Hyo S., Vojnović, Željko, Vasev, Nikola, Ma, Ling, Richards, Donald A., Wilks, Sharon T., Milenković, Dušan, Xiao, Jie, Sorrentino, Jessica, Horton, Janet, O'Shaughnessy, Joyce
Publicado 2022

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York...

por Adelson, Kerin, Ramaswamy, Bhuvaneswari, Sparano, Joseph A, Christos, Paul J, Wright, John J, Raptis, George, Han, Gang, Villalona-Calero, Miguel, Ma, Cynthia X, Hershman, Dawn, Baar, Joseph, Klein, Paula, Cigler, Tessa, Budd, G Thomas, Novik, Yelena, Tan, Antoinette R, Tannenbaum, Susan, Goel, Anupama, Levine, Ellis, Shapiro, Charles L, Andreopoulou, Eleni, Naughton, Michael, Kalinsky, Kevin, Waxman, Sam, Germain, Doris
Publicado 2016

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

por Hirshfield, Kim M., Tolkunov, Denis, Zhong, Hua, Ali, Siraj M., Stein, Mark N., Murphy, Susan, Vig, Hetal, Vazquez, Alexei, Glod, John, Moss, Rebecca A., Belyi, Vladimir, Chan, Chang S., Chen, Suzie, Goodell, Lauri, Foran, David, Yelensky, Roman, Palma, Norma A., Sun, James X., Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Kaufman, Howard, Poplin, Elizabeth, Mehnert, Janice, Tan, Antoinette R., Bertino, Joseph R., Aisner, Joseph, DiPaola, Robert S., Rodriguez-Rodriguez, Lorna, Ganesan, Shridar
Publicado 2016